Global Multiple Sclerosis Drugs Market: Overview
The global market for multiple sclerosis
drugs is heavily influenced by the significant increase in the patient
pool suffering from secondary progressive and relapsing-remitting
multiple sclerosis. The augmenting demand for novel potent drugs for the
treatment of multiple sclerosis and the presence of a robust drug
pipeline are also propelling this market substantially. Over the
forthcoming years, the projected commercialization of drugs that are
currently in development phase, such as Zinbryta and Ocrelizumab, is
likely to reflect greatly on this market.
This research study, prepared using a
number of paid and unpaid sources, offers a detailed assessment of the
global market for multiple sclerosis drugs. It is a highly dependable
business tool, which assists in identifying prominent trends and growth
prospects of this market at both, regional as well as international
level. It also presents quantitative and qualitative insights into the
competitive landscape of this market by profiling the key enterprises on
the basis of their market shares, latest development, business
strategies, product details, revenue structure, and contact information.
It further performs a SWOT analysis of each of the market players that
reveals their potential growth trajectory. In the report, the worldwide
market for multiple sclerosis is analyzed on the basis of the drug
class, mode of administration, and geographical spread of this market
for a coherent understanding.
Global Multiple Sclerosis Drugs Market: Trends and Opportunities
Of late, the escalating prevalence of
multiple sclerosis and the extensive research and development pipelines
are the prime driving force behind the tremendous growth of the global
market multiple sclerosis drugs. In addition to this, the increased
research in the field of multiple sclerosis for the development of
innovative therapies is likely to boost this market significantly in the
forthcoming years.
On the other hand, patent expiry of
various blockbuster drugs may create an obstruction in the growth
trajectory of this market. Besides, the stringent regulatory hurdles are
also projected to restrict this market from rising steadily. However,
advancements in biomedical science will create a lucrative opportunity
for drugmakers in the near future. The rising mergers and acquisitions
between these vendors and the ongoing product launches will also
influence this market greatly in the coming years.
Immunomodulators (Avonex/Plegridy,
Copaxone, Gilneya, Betaseron/Extavia, Tysabri, Rebif, Tecifidera, and
Ampyra) and immunosuppressant (Ocrelizumab, Lemtrada, Aubagio, and
Zinbryta) have emerged as the most preferred drug classes used for the
treatment of multiple sclerosis and its associated symptoms. Researchers
expect this scenario to remain so over the next few years.
Oral, injectable, and intravenous have
been identified as the main modes of administration of multiple
sclerosis drugs across the world. The demand for oral drugs is higher
and is expected to remain so over the forthcoming years.
Global Multiple Sclerosis Drugs Market: Geographical Analysis
North America, Europe, Asia Pacific, and
the Rest of the World are considered as the predominant geographical
segments of the global market for multiple sclerosis drugs. Among these,
North America dominates the overall market, thanks to the presence of a
state-of-art medical and healthcare infrastructure. In this region, the
U.S. has acquired the topmost position and is trailed by Canada.
Europe and Asia Pacific are also
experiencing a robust rise in the demand for multiple sclerosis drugs.
In Europe, Spain, Germany, France, Italy, and the U.K. have been leading
the market for multiple sclerosis drugs. China, Japan, and India are
key contributors to the market for multiple sclerosis drugs in Asia
Pacific. The Asia Pacific market is likely to exhibit a higher growth
rate than other regional markets over the next few years, thanks to the
increasing construction manufacturing and research facilities of a
number of leading manufacturers of multiple sclerosis drugs.
Companies mentioned in this report
At the forefront of the global market for
multiple sclerosis drugs are Biogen Idec, Bayer Healthcare, Teva
Pharmaceuticals, Pfizer, Merck, Sanofi-Aventis, and Novartis. The ample
presence of unmet needs and the growing demand for highly effective and
fast-acting drugs are expected to prompt drugmakers to modify their
existing product portfolio in the near future.
No comments:
Post a Comment